Copyright
©The Author(s) 2015.
World J Cardiol. Nov 26, 2015; 7(11): 792-800
Published online Nov 26, 2015. doi: 10.4330/wjc.v7.i11.792
Published online Nov 26, 2015. doi: 10.4330/wjc.v7.i11.792
Table 1 Patient demographics and comorbidities
Variable | Total (n = 200) | BTT (n = 98) | DT (n = 102) | P value |
Age (yr) | 54.3 ± 12.5 | 50.1 ± 12.8 | 58.4 ± 10.7 | 0.001 |
Gender | ||||
Female | 24% (48/200) | 25.5% (25/98) | 22.8% (23/102) | |
Male | 76% (151/200) | 74.5% (73/98) | 76.5% (78/102) | 0.652 |
Race | ||||
AA | 46% (92/200) | 39.8% (39/98) | 52% (53/102) | 0.375 |
Caucasian | 54% (108/200) | 54.1% (53/98) | 42.4% (47/102) | |
Etiology of heart failure | ||||
ICM | 52% (104/200) | 29% (28/98) | 74.5% (76/102) | 0.001 |
NIDCM | 48% (96/200) | 51% (50/98) | 45.1% (46/102) | |
BSA | 1.97 ± 0.27 | 1.96 ± 0.27 | 1.98 ± 0.28 | 0.667 |
BMI | 28.3 ± 5.5 | 28.1 ± 4.3 | 28.5 ± 6.5 | 0.763 |
Albumin (g/dL) | 4.14 ± 10.03 | 3.19 ± 0.51 | 5.06 ± 14.05 | 0.015 |
DM | 46% (92/200) | 38.8% (38/98) | 52.9% (54/102) | 0.038 |
HTN | 83% (166/200) | 79.6% (78/98) | 86.2% (88/102) | 0.153 |
CRI | 40% (81/200) | 29.6% (29/98) | 51% (52/102) | 0.002 |
Dialysis | 2.5% (5/200) | 3.1% (3/98) | 1.8% (2/102) | 0.680 |
COPD | 15.5% (31/200) | 15.3% (15/98) | 15.7% (16/102) | 0.917 |
PVD | 12% (23/200) | 7.1% (7/98) | 15.7% (16/102) | 0.055 |
Vented | 12% (25/200) | 9.2% (9/98) | 15.7% (16/102) | 0.134 |
Previous cardiac surgery | 32% (63/200) | 20.4% (20/98) | 42% (43/102) | 0.001 |
Creatinine (mg/dL) | 1.42 ± 0.62 | 1.43 ± 0.58 | 1.42 ± 0.65 | 0.869 |
AST (U/L) | 48.3 ± 82.8 | 58.0 ± 106.8 | 38.9 ± 45.7 | 0.212 |
ALT (U/L) | 46.5 ± 78.5 | 59.8 ± 99.4 | 33.5 ± 47.3 | 0.002 |
CPB time (min) | 113.5 ± 46.1 | 109.5 ± 46.0 | 117.8 ± 46.1 | 0.178 |
XCL time (min) | 71 ± 30.6 | 85.2 ± 33.7 | 51.7 ± 26.0 | 0.054 |
MCS at time of VAD | 18% (36/200) | 24% (23/98) | 13% (13/102) | 0.051 |
On inotropes at time of VAD | 75%(150/200) | 81% (80/98) | 69% (70/102) | 0.036 |
Pre VAD CVP (mmHg) | 11.8 ± 6.4 | 11.6 ± 6.4 | 12.0 ± 6.4 | 0.653 |
Pre VAD PAPs (mmHg) | 51.4 ± 14.2 | 50.5 ± 14.5 | 52.3 ± 13.8 | 0.412 |
Pre VAD PAPd (mmHg) | 24.5 ± 9.2 | 24.4 ± 9.8 | 24.7 ± 8.5 | 0.682 |
Pre Vad CI (L/min per square metre) | 1.85 ± 0.51 | 1.87 ± 0.54 | 1.83 ± 0.47 | 0.961 |
Pre VAD PCWP (mmHg) | 23.0 ± 9.6 | 22.7 ± 9.8 | 23.4 ± 9.4 | 0.463 |
Blood transfusions | 23% (46/200) | 18% (18/98) | 27% (28/102) | 0.250 |
Concomitant cardiac procedure | 19% (39/200) | 23% (23/98) | 15% (16/102) | 0.137 |
Table 2 Postoperative outcomes
Variable | Total (n = 200) | BTT (n = 98) | DT (n = 102) | P value |
Postoperative ICU stay (d) | 195 10.7 ± 10.4 | 95 10.2 ± 7.7 | 100 11.2 ± 12.5 | 0.833 |
Overall length of stay (d) | 198 21.4 ± 14.3 | 98 20.8 ± 12.9 | 100 22.1 ± 15.6 | 0.517 |
Readmitted within 30 d | 26.5% (53/200) | 26.0 (25/96) | 27% (28/102) | 0.725 |
Reexploration for bleeding | 15% (31/200) | 10% (10/98) | 5% (6/102) | 0.040 |
DL infection | 7% (15/200) | 9% (9/98) | 5% (6/102) | 0.386 |
Pocket infection | 1% (2/200) | 1% (1/98) | 1% (1/102) | 0.493 |
Pneumonia | 7% (15/200) | 9% (9/98) | 5% (6/102) | 0.375 |
Hemorrhagic stroke | 10% (21/200) | 9% (9/98) | 11% (12/102) | 0.432 |
Emboli stroke | 5% (10/200) | 6% (6/98) | 3% (4/102) | 0.493 |
VDRF | 9% (19/200) | 10% (10/98) | 8% (9/102) | 0.774 |
Tracheostomy | 2% (5/200) | 1% (1/98) | 3% (4/102) | 0.369 |
Dialysis | 2% (5/200) | 3% (3/98) | 1% (2/102) | 0.680 |
GIB | 21% (43/200) | 17% (17/98) | 25% (26/102) | 0.289 |
Reoperation for Al | 2% (4/200) | 4% (4/98) | 0% (0/102) | 0.058 |
RV failure | 19% (38/200) | 15% (15/98) | 22% (23/102) | 0.192 |
RV failure requiring milrinone | 13% (26/200) | 9% (9/98) | 16% (17/102) | 0.103 |
RV failure requiring RVAD | 6% (12/200) | 6% (6/98) | 5% (6/102) | 0.803 |
Heart transplant | 27% (55/200) | 45% (45/98) | 10% (10/102) | 0.001 |
Duration of support (d) | 581.0 ± 517.9 | 554.8 ± 535.0 | 606.4 ± 502.1 | 0.253 |
Table 3 Outcomes for bridge to transplan and destination therapy patients
Variable | Patients (%) | |
BTT | Died | 28.6 (28/98) |
Ongoing | 25.5 (25/98) | |
Transplant | 45.9 (45/98) | |
DT | Died | 34.3 (35/102) |
Ongoing | 54.8 (56/102) | |
Transplant | 9.8 (10/102) |
Table 4 Hemodymanic measurements pre and post left ventricular assist device at 6 mo
Variables | Pre VAD | Post VAD | P value |
CVP (mmHg) | 12 ± 6 | 8 ± 4.5 | 0.001 |
PAPs (mmHg) | 53.52 ± 13.76 | 36.03 ± 11.85 | 0.001 |
PAPd (mmHg) | 26.15 ± 9.50 | 16.11 ± 6.24 | 0.001 |
CI (L/min per square meter) | 1.78 ± 0.39 | 2.52 ± 0.60 | 0.001 |
PCWP (mmHg) | 25.09 ± 10.05 | 11.93 ± 7.84 | 0.001 |
LVEDD (mm) | 71.70 ± 13.61 | 57.45 ± 15.3 | 0.001 |
LVEF (%) | 16 ± 7.90 | 21 ± 9.00 | 0.017 |
Table 5 Multiple cox proportional hazard models
Variable | HR 95%CI | P value | Backwards stepwise model |
Albumin | 0.64 (0.27, 1.52) | 0.310 | |
Length of stay | 0.85 (0.62, 1.17) | 0.319 | |
CPB time | 1.05 (0.98, 1.14) | 0.175 | |
CRI | 1.13 (0.44, 2.91) | 0.804 | |
PVD | 0.95 (0.30, 3.03) | 0.931 | |
Vented | 0.93 (0.17, 4.97) | 0.929 | |
Creatinine | 0.77 (0.37, 1.63) | 0.495 | |
PreVAD AST | 1.03 (1.00, 1.07) | 0.072 | 1.03 (1.01, 1.05) 0.01 |
PreVAD ALT | 1.02 (1.00, 1.05) | 0.064 | 1.02 (1.01, 1.04) 0.02 |
Blood transfusion | 1.19 (0.45, 3.14) | 0.732 | |
ICU stay | 0.80 (0.52, 1.24) | 0.320 | |
Reexploration | 1.70 (0.50, 5.79) | 0.794 | |
VDRF | 4.92 (1.62, 14.93) | 0.005 | 3.05 (1.41, 6.59) 0.005 |
Tracheostomy | 5.53 (0.65, 46.78) | 0.116 | 4.54 (1.35, 15.32) 0.015 |
RV failure | 0.45 (0.09, 2.26) | 0.330 | |
RVAD | 8.90 (1.30, 61.06) | 0.066 | 3.64 (1.59, 8.36) 0.002 |
Age | 1.02 (0.95, 1.12 ) | 0.176 | |
Gender | 0.75 (0.66, 1.56 ) | 0.321 | |
Resternotomy | 1.31 (0.83, 4.55) | 0.673 | |
Etiology of heart failure | 1.23 (0.59, 4.08) | 0.512 |
- Citation: Tsiouris A, Paone G, Nemeh HW, Borgi J, Williams CT, Lanfear DE, Morgan JA. Short and long term outcomes of 200 patients supported by continuous-flow left ventricular assist devices. World J Cardiol 2015; 7(11): 792-800
- URL: https://www.wjgnet.com/1949-8462/full/v7/i11/792.htm
- DOI: https://dx.doi.org/10.4330/wjc.v7.i11.792